Heart disease has held the grim distinction of being the leading cause of death in the United States for decades, and despite advances in medicine, the problem is getting worse, not better. According to the American Heart Association (“AHA”), cardiovascular disease accounted for more than 940,000 deaths in the United States in 2022, maintaining its position as the nation’s number one killer. Into that persistent and costly healthcare burden steps Cardio Diagnostics Holdings (NASDAQ: CDIO), a Chicago-based precision cardiovascular medicine company that is applying artificial intelligence, epigenetics and genetics to a problem that traditional diagnostic tools have never fully solved: detecting coronary heart disease, including forms that standard methods routinely miss, from a simple blood draw.
For cardiovascular conditions, annual health care costs are forecasted to increase from $393 billion in 2020 to $1.4 trillion by 2050, almost quadrupling in size. What makes Cardio Diagnostics’ approach distinct, and what gives the company a defensible clinical position, is its ability to detect coronary heart disease earlier and with high sensitivity. The company’s recent commercial and regulatory milestones give additional shape to the investment thesis.
The scale of the problem that Cardio Diagnostics is working to address is difficult to overstate. According to the AHA, cardiovascular disease remains the leading cause of death across men, women, and most racial and ethnic groups in the nation, with one person dying every 34 seconds from the condition. By leveraging epigenetics—the study of changes in gene expression that do not involve alterations to the DNA sequence—and AI algorithms, Cardio Diagnostics aims to identify patients at risk before symptoms manifest, potentially shifting the paradigm from reactive to preventive cardiology.
The company’s technology platform is designed to integrate with existing healthcare workflows, offering a non-invasive test that could be administered in a primary care setting. This accessibility is crucial because many patients with early-stage heart disease are asymptomatic and are often diagnosed only after a major cardiac event. The implications of such a diagnostic tool are profound: earlier detection could reduce mortality rates, lower healthcare costs, and improve quality of life for millions.
For more information on Cardio Diagnostics and its innovative approach, readers can visit the company’s newsroom at https://ibn.fm/CDIO. The company’s forward-looking statements, including those related to regulatory approvals and commercialization, are subject to risks and uncertainties detailed in its filings with the SEC. As Cardio Diagnostics continues to advance its technology, the potential to transform cardiovascular care and address a $393 billion public health challenge becomes increasingly tangible.
